FAAH
A Hidrolase de Amida de Ácido Graxo (FAAH) é uma enzima que degrada amidas de ácidos graxos, incluindo endocanabinoides como a anandamida. Esses compostos estão envolvidos na regulação da dor, humor, apetite e memória. A inibição da FAAH pode aumentar os níveis dessas moléculas de sinalização, oferecendo potenciais benefícios terapêuticos para dor, ansiedade e doenças neurodegenerativas. Na CymitQuimica, oferecemos uma seleção de inibidores de FAAH para apoiar sua pesquisa em neurociência, manejo da dor e sinalização endocanabinoide.
Foram encontrados 63 produtos de "FAAH"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FAAH/cPLA2α-IN-1
CAS:<p>FAAH/cPLA2α-IN-1 is a compound that simultaneously inhibits both FAAH and cPLA2α, demonstrating potent activity with half-maximal inhibitory concentrations (</p>Fórmula:C19H26N4O5Pureza:98%Cor e Forma:SolidPeso molecular:390.43OMDM-5
CAS:<p>OMDM-5 is a potent vanilloid receptor type 1 (TRPV1, EC50 = 75 nM) agonist, showing weak ligand activity at cannabinoid type 1 receptor (CB1, Ki=4.9 μM).</p>Fórmula:C26H44N2O3Pureza:99.73%Cor e Forma:SolidPeso molecular:432.64JP104
CAS:<p>JP104 is an aryl carbamate that irreversibly inhibits fatty acid amide hydrolase (FAAH) with a pIC50 value of approximately 8 [1].</p>Fórmula:C25H30N2O3Pureza:98%Cor e Forma:SolidPeso molecular:406.523-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone
CAS:<p>3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone (compound 45), having a pI50 of 5.89, shows promise as an inhibitor of fatty acid amide hydrolase (FAAH). Despite its activity, it demonstrates a lack of affinity for cannabinoid receptors CB(1) and CB(2) [1].</p>Fórmula:C25H32N2OSCor e Forma:SolidPeso molecular:408.6FAAH inhibitor 2
CAS:<p>FAAH Inhibitor 2 (Compound 17b) is an irreversible inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 value of 0.153 μM [1].</p>Fórmula:C24H40N2O2Cor e Forma:SolidPeso molecular:388.59Sob-AM2
CAS:<p>Sob-AM2 is an effective substrate targeting the fatty acid amide hydrolase (FAAH) expressed in the brain, with a Km of 1.3 μM. It delivers higher concentrations of Sobetirome to the central nervous system at minimal peripheral systemic doses, thereby activating the central thyroid hormone receptor β (TRβ).</p>Fórmula:C21H27NO3Cor e Forma:SolidPeso molecular:341.44MK-3168 (12C)
CAS:<p>MK-3168 (12C) functions as a FAAH inhibitor, exhibiting IC50 values of 1.0 nM, 5.5 nM, and 1.7 nM for human, rhesus, and rat respectively. It demonstrates effective brain uptake and FAAH-specific signaling. Additionally, 11 C MK-3168 is applicable as a FAAH PET tracer.</p>Fórmula:C21H21ClN4OSCor e Forma:SolidPeso molecular:412.94FAAH/MAGL-IN-1
<p>FAAH/MAGL-IN-1 (SIH 3) inhibits FAAH & MAGL with IC50 of 31 & 29 nM, useful in neuropathic pain research.</p>Fórmula:C15H9Cl2N3O3Cor e Forma:SolidPeso molecular:350.16FAAH/MAGL-IN-2
CAS:<p>FAAH/MAGL-IN-2: potent, reversible, oral FAAH & MAGL inhibitor, IC50: 11/36 nM, may research neuropathic pain, no locomotion issue.</p>Fórmula:C15H13Cl2N3O3SCor e Forma:SolidPeso molecular:386.25FAAH/MAGL-IN-3
<p>FAAH/MAGL-IN-3 irreversibly inhibits FAAH (IC50: 179 nM) & MAGL (IC50: 759 nM) with low PAMPA permeability.</p>Fórmula:C21H25N3O6SCor e Forma:SolidPeso molecular:447.5AZ513
CAS:<p>AZ513 is a reversible FAAH inhibitor, exhibiting an IC50 of 551 nM for human FAAH and 27 nM for rat FAAH. It inhibits the hydrolysis of arachidonoyl ethanolamide in HEK293 cells transfected with human FAAH, with an IC50 of 360 nM.</p>Fórmula:C14H9Cl2N3OCor e Forma:SolidPeso molecular:306.147Dual FAAH/sEH-IN-1
CAS:<p>Dual FAAH/sEH-IN-1 inhibits both sEH (IC50: 9.6 nM) and FAAH (IC50: 7 nM), offering potent anti-inflammatory effects.</p>Fórmula:C25H22ClN3O3S2Pureza:99.89%Cor e Forma:SolidPeso molecular:512.04TC-F 2
CAS:<p>TC-F 2 is a FAAH inhibitor.</p>Fórmula:C26H25N5O2Pureza:98%Cor e Forma:SolidPeso molecular:439.51
